社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
AppleSeed
IP属地：未知
+关注
帖子 · 42
帖子 · 42
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
AppleSeed
AppleSeed
·
2021-12-30
👌🏻
非常抱歉，此主贴已删除
看
1,811
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
AppleSeed
AppleSeed
·
2021-12-30
👍🏻
Samsung BioLogics says report on Biogen deal talks untrue
Dec 29 (Reuters) - Samsung BioLogics on Thursday denied a media report that said the South Korean fi
Samsung BioLogics says report on Biogen deal talks untrue
看
1,727
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
AppleSeed
AppleSeed
·
2021-12-30
👍🏻
How Long Will Virgin Galactic Stock's Downward Spiral Last?
Virgin Galactic Holdings Inc. shares lost altitude Wednesday, continuing the downward spiral the sto
How Long Will Virgin Galactic Stock's Downward Spiral Last?
看
1,769
回复
评论
点赞
1
编组 21备份 2
分享
举报
AppleSeed
AppleSeed
·
2021-12-30
👍🏻
Want $1 Million? Buy and Hold These 2 Stocks for the Next Decade
These two stocks could provide life-changing returns in 10 years.
Want $1 Million? Buy and Hold These 2 Stocks for the Next Decade
看
1,708
回复
1
点赞
1
编组 21备份 2
分享
举报
AppleSeed
AppleSeed
·
2021-12-30
👍🏻
3 Rookie Mistakes to Avoid Making in the Stock Market
Now is a time to exercise more caution when picking stocks.
3 Rookie Mistakes to Avoid Making in the Stock Market
看
2,892
回复
评论
点赞
2
编组 21备份 2
分享
举报
AppleSeed
AppleSeed
·
2021-12-29
Thank you and wishing everyone a prosperous 2022.
看
1,587
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
AppleSeed
AppleSeed
·
2021-12-22
👍🏻
5 Beaten-Down Growth Stocks That Can Soar in 2022
These high-flying stocks have all the tools necessary to regain their luster over the next year.
5 Beaten-Down Growth Stocks That Can Soar in 2022
看
1,742
回复
1
点赞
1
编组 21备份 2
分享
举报
AppleSeed
AppleSeed
·
2021-12-13
👍🏻
Charlie Munger: This market is 'even crazier' than the dot-com bust — here are 3 contrarian stocks to help you sidestep the herd
Berkshire Hathaway Vice Chairman Charlie Munger tends to be much more direct with his warnings and c
Charlie Munger: This market is 'even crazier' than the dot-com bust — here are 3 contrarian stocks to help you sidestep the herd
看
2,492
回复
1
点赞
7
编组 21备份 2
分享
举报
AppleSeed
AppleSeed
·
2021-12-12
👍🏻
At Its Highest Price in a Decade, Can Bank of America Go Higher in 2022?
The bank now trades at a strong valuation but also has a good outlook for 2022.
At Its Highest Price in a Decade, Can Bank of America Go Higher in 2022?
看
2,171
回复
2
点赞
3
编组 21备份 2
分享
举报
AppleSeed
AppleSeed
·
2021-12-10
👍🏻
非常抱歉，此主贴已删除
看
1,840
回复
1
点赞
2
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3575018034770296","uuid":"3575018034770296","gmtCreate":1611924011245,"gmtModify":1616122050318,"name":"AppleSeed","pinyin":"appleseed","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/dd7084b7c374d1c9d55f5a6efe3e1115","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":7,"headSize":96,"tweetSize":42,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":3,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.06.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.23","exceedPercentage":"80.10%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.82%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":6,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":692366748,"gmtCreate":1640852437196,"gmtModify":1640852437313,"author":{"id":"3575018034770296","authorId":"3575018034770296","name":"AppleSeed","avatar":"https://static.tigerbbs.com/dd7084b7c374d1c9d55f5a6efe3e1115","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575018034770296","authorIdStr":"3575018034770296"},"themes":[],"htmlText":"👌🏻","listText":"👌🏻","text":"👌🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692366748","repostId":"1192038326","repostType":4,"isVote":1,"tweetType":1,"viewCount":1811,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692366670,"gmtCreate":1640852395109,"gmtModify":1640852395264,"author":{"id":"3575018034770296","authorId":"3575018034770296","name":"AppleSeed","avatar":"https://static.tigerbbs.com/dd7084b7c374d1c9d55f5a6efe3e1115","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575018034770296","authorIdStr":"3575018034770296"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692366670","repostId":"1144072990","repostType":4,"repost":{"id":"1144072990","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640846286,"share":"https://ttm.financial/m/news/1144072990?lang=&edition=full","pubTime":"2021-12-30 14:38","market":"us","language":"en","title":"Samsung BioLogics says report on Biogen deal talks untrue","url":"https://stock-news.laohu8.com/highlight/detail?id=1144072990","media":"Reuters","summary":"Dec 29 (Reuters) - Samsung BioLogics on Thursday denied a media report that said the South Korean fi","content":"<html><head></head><body><p>Dec 29 (Reuters) - Samsung BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc.</p><p>Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen had approached Samsung to buy its shares, which could be valued at more than $42 billion. Biogen is valued at $34.67 billion, according to Refinitiv data.</p><p>Samsung BioLogics, the biotech unit of Samsung Group, said in a regulatory filing that the report was "not true," without giving any more details.</p><p>Biogen said it does not comment on market rumors or speculation. Its stock closed up 9.5% on Wednesday.</p><p>Any such deal would be the biggest overseas acquisition ever by a South Korean company. The largest so far was in 2016, when Samsung Electronics bought auto electronics maker Harman International Industries in an $8 billion deal.</p><p>Samsung Group had said earlier this year it will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era.</p><p>In June, Biogen's controversial Alzheimer's drug won U.S. regulatory approval, becoming the first new treatment for the memory-robbing disease in nearly 20 years, despite an outside advisory panel's view that the company had not proven the treatment's clinical benefits.</p><p>Biogen has been betting on the drug, Aduhelm, to buffer a hit as its main revenue drivers such as multiple sclerosis treatment Tecfidera and muscle disease treatment Spinraza face rising competition.</p><p>But U.S. sales from Aduhelm have been slower than expected as hospitals complained that the drug's high cost was not worth its benefits. The company cut its price by about half to $28,200 this month.</p><p>Biogen, which makes drugs for neurological diseases, currently has more than 30 new drugs in its pipeline.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Samsung BioLogics says report on Biogen deal talks untrue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSamsung BioLogics says report on Biogen deal talks untrue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-30 14:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Dec 29 (Reuters) - Samsung BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc.</p><p>Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen had approached Samsung to buy its shares, which could be valued at more than $42 billion. Biogen is valued at $34.67 billion, according to Refinitiv data.</p><p>Samsung BioLogics, the biotech unit of Samsung Group, said in a regulatory filing that the report was "not true," without giving any more details.</p><p>Biogen said it does not comment on market rumors or speculation. Its stock closed up 9.5% on Wednesday.</p><p>Any such deal would be the biggest overseas acquisition ever by a South Korean company. The largest so far was in 2016, when Samsung Electronics bought auto electronics maker Harman International Industries in an $8 billion deal.</p><p>Samsung Group had said earlier this year it will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era.</p><p>In June, Biogen's controversial Alzheimer's drug won U.S. regulatory approval, becoming the first new treatment for the memory-robbing disease in nearly 20 years, despite an outside advisory panel's view that the company had not proven the treatment's clinical benefits.</p><p>Biogen has been betting on the drug, Aduhelm, to buffer a hit as its main revenue drivers such as multiple sclerosis treatment Tecfidera and muscle disease treatment Spinraza face rising competition.</p><p>But U.S. sales from Aduhelm have been slower than expected as hospitals complained that the drug's high cost was not worth its benefits. The company cut its price by about half to $28,200 this month.</p><p>Biogen, which makes drugs for neurological diseases, currently has more than 30 new drugs in its pipeline.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144072990","content_text":"Dec 29 (Reuters) - Samsung BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc.Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen had approached Samsung to buy its shares, which could be valued at more than $42 billion. Biogen is valued at $34.67 billion, according to Refinitiv data.Samsung BioLogics, the biotech unit of Samsung Group, said in a regulatory filing that the report was \"not true,\" without giving any more details.Biogen said it does not comment on market rumors or speculation. Its stock closed up 9.5% on Wednesday.Any such deal would be the biggest overseas acquisition ever by a South Korean company. The largest so far was in 2016, when Samsung Electronics bought auto electronics maker Harman International Industries in an $8 billion deal.Samsung Group had said earlier this year it will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era.In June, Biogen's controversial Alzheimer's drug won U.S. regulatory approval, becoming the first new treatment for the memory-robbing disease in nearly 20 years, despite an outside advisory panel's view that the company had not proven the treatment's clinical benefits.Biogen has been betting on the drug, Aduhelm, to buffer a hit as its main revenue drivers such as multiple sclerosis treatment Tecfidera and muscle disease treatment Spinraza face rising competition.But U.S. sales from Aduhelm have been slower than expected as hospitals complained that the drug's high cost was not worth its benefits. The company cut its price by about half to $28,200 this month.Biogen, which makes drugs for neurological diseases, currently has more than 30 new drugs in its pipeline.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":1727,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692366196,"gmtCreate":1640852319419,"gmtModify":1640852319578,"author":{"id":"3575018034770296","authorId":"3575018034770296","name":"AppleSeed","avatar":"https://static.tigerbbs.com/dd7084b7c374d1c9d55f5a6efe3e1115","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575018034770296","authorIdStr":"3575018034770296"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692366196","repostId":"1175352360","repostType":4,"repost":{"id":"1175352360","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640848220,"share":"https://ttm.financial/m/news/1175352360?lang=&edition=full","pubTime":"2021-12-30 15:10","market":"us","language":"en","title":"How Long Will Virgin Galactic Stock's Downward Spiral Last?","url":"https://stock-news.laohu8.com/highlight/detail?id=1175352360","media":"Benzinga","summary":"Virgin Galactic Holdings Inc. shares lost altitude Wednesday, continuing the downward spiral the sto","content":"<html><head></head><body><p><b>Virgin Galactic Holdings Inc.</b> shares lost altitude Wednesday, continuing the downward spiral the stock has been on for months. The stock recently broke below a key level that it has been able to hold as support many times in the past.</p><p>Virgin Galactic was down 5.58% at $13.04 at the close.</p><p>Virgin Galactic Daily Chart Analysis</p><ul><li>Shares fell below the key $15 level and have been falling since July 2021. The stock was unable to hold above the $24 level where it also found support in the past and has now fallen out of the sideways channel in which it traded.</li><li>The stock trades below both the 50-day moving average (green) and the 200-day moving average (blue). This indicates the sentiment is bearish, and each of these moving averages may hold as an area of resistance in the future.</li><li>The Relative Strength Index (RSI) has been moving sideways below the middle line and sits at 28 on the indicator. This shows that the stock is in the oversold range and the selling pressure is heavily outweighing the buying pressure.</li></ul><p><img src=\"https://static.tigerbbs.com/c5cc2b781eae34a706b0c9fa5a407302\" tg-width=\"2400\" tg-height=\"1175\" width=\"100%\" height=\"auto\"/></p><p><b>What’s Next For Virgin Galactic?</b></p><p>Virgin Galactic has been on a downward spiral for the last half of the year and has fallen below all support lines. This shows bears are in full control of the stock and would like to see the stock continue to fall and hold below the moving averages.</p><p>Bulls on the other hand would like to see the stock make a bounce and be able to cross back above the $15 support line and be able to hold above it once again. Bulls are then looking for a cross back above the moving averages for sentiment to turn bullish once again.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Long Will Virgin Galactic Stock's Downward Spiral Last?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Long Will Virgin Galactic Stock's Downward Spiral Last?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-30 15:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><b>Virgin Galactic Holdings Inc.</b> shares lost altitude Wednesday, continuing the downward spiral the stock has been on for months. The stock recently broke below a key level that it has been able to hold as support many times in the past.</p><p>Virgin Galactic was down 5.58% at $13.04 at the close.</p><p>Virgin Galactic Daily Chart Analysis</p><ul><li>Shares fell below the key $15 level and have been falling since July 2021. The stock was unable to hold above the $24 level where it also found support in the past and has now fallen out of the sideways channel in which it traded.</li><li>The stock trades below both the 50-day moving average (green) and the 200-day moving average (blue). This indicates the sentiment is bearish, and each of these moving averages may hold as an area of resistance in the future.</li><li>The Relative Strength Index (RSI) has been moving sideways below the middle line and sits at 28 on the indicator. This shows that the stock is in the oversold range and the selling pressure is heavily outweighing the buying pressure.</li></ul><p><img src=\"https://static.tigerbbs.com/c5cc2b781eae34a706b0c9fa5a407302\" tg-width=\"2400\" tg-height=\"1175\" width=\"100%\" height=\"auto\"/></p><p><b>What’s Next For Virgin Galactic?</b></p><p>Virgin Galactic has been on a downward spiral for the last half of the year and has fallen below all support lines. This shows bears are in full control of the stock and would like to see the stock continue to fall and hold below the moving averages.</p><p>Bulls on the other hand would like to see the stock make a bounce and be able to cross back above the $15 support line and be able to hold above it once again. Bulls are then looking for a cross back above the moving averages for sentiment to turn bullish once again.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPCE":"维珍银河"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175352360","content_text":"Virgin Galactic Holdings Inc. shares lost altitude Wednesday, continuing the downward spiral the stock has been on for months. The stock recently broke below a key level that it has been able to hold as support many times in the past.Virgin Galactic was down 5.58% at $13.04 at the close.Virgin Galactic Daily Chart AnalysisShares fell below the key $15 level and have been falling since July 2021. The stock was unable to hold above the $24 level where it also found support in the past and has now fallen out of the sideways channel in which it traded.The stock trades below both the 50-day moving average (green) and the 200-day moving average (blue). This indicates the sentiment is bearish, and each of these moving averages may hold as an area of resistance in the future.The Relative Strength Index (RSI) has been moving sideways below the middle line and sits at 28 on the indicator. This shows that the stock is in the oversold range and the selling pressure is heavily outweighing the buying pressure.What’s Next For Virgin Galactic?Virgin Galactic has been on a downward spiral for the last half of the year and has fallen below all support lines. This shows bears are in full control of the stock and would like to see the stock continue to fall and hold below the moving averages.Bulls on the other hand would like to see the stock make a bounce and be able to cross back above the $15 support line and be able to hold above it once again. Bulls are then looking for a cross back above the moving averages for sentiment to turn bullish once again.","news_type":1,"symbols_score_info":{"SPCE":0.9}},"isVote":1,"tweetType":1,"viewCount":1769,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692366933,"gmtCreate":1640852291033,"gmtModify":1640852291191,"author":{"id":"3575018034770296","authorId":"3575018034770296","name":"AppleSeed","avatar":"https://static.tigerbbs.com/dd7084b7c374d1c9d55f5a6efe3e1115","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575018034770296","authorIdStr":"3575018034770296"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/692366933","repostId":"2195454191","repostType":4,"repost":{"id":"2195454191","kind":"highlight","pubTimestamp":1640852195,"share":"https://ttm.financial/m/news/2195454191?lang=&edition=full","pubTime":"2021-12-30 16:16","market":"us","language":"en","title":"Want $1 Million? Buy and Hold These 2 Stocks for the Next Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2195454191","media":"Motley Fool","summary":"These two stocks could provide life-changing returns in 10 years.","content":"<html><head></head><body><p>The stock market has had <a href=\"https://laohu8.com/S/AONE.U\">one</a> of its best decades ever, with the <b>SPDR S&P 500 ETF</b> providing 275% returns over the past 10 years. While this performance is extremely impressive, I believe there are two stocks that could outperform the market and provide multibagger returns over the next decade.</p><p>If you add <b>Doximity</b> (NYSE:DOCS) and <b>DermTech</b> (NASDAQ:DMTK) to a diversified portfolio, they could help you turn $100,000 into $1 million over the next decade. Here's how.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31ce77a52792905dc64e60dfc5da1196\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images</span></p><h2>Doximity: A doctor's social media</h2><p>While many business professionals use <b>Microsoft</b>'s LinkedIn, nearly 80% of medical professionals in the U.S. use Doximity. Doximity serves as a career growth app, a messaging app, an educational resource, and a social media platform all in one for doctors. In addition, Doximity offers telehealth accessibility, making it the super app for doctors and healthcare professionals.</p><p>Doximity has truly become a primary platform that medical professionals use. Aside from the 80% of doctors on the platform, 50% of nurse practitioners and physician assistants use it, and a staggering 90% of medical students use it -- signaling that Doximity will continue to be the place where medical workers should go to collaborate, communicate, and expand their careers. As a result, Doximity's platform has attracted lots of advertisers.</p><p>Doximity makes money from advertising revenue from pharmaceutical companies looking to show doctors their drugs on the research part of its app that delivers personalized news and research to doctors. Over 600 pharmaceutical companies are desperate to get their products in front of doctors and potential buyers, 200 of which spend over $100,000 per year to do so. What is most impressive is that Doximity's net retention rate is 173% -- meaning these customers spent 73 cents more in Q3 2021 on top of every dollar they spent in the year-ago quarter, including churning customers.</p><p>In addition, 93% of Doximity's revenue comes from subscriptions from pharmaceutical companies. Because of this focus on subscriptions, its gross margins are a lofty 89%. Another factor making this company a financial powerhouse is the 80% share of U.S, doctors already on the platform, which means Doximity does not have to spend a ton on operating expenses. This allows for Doximity to bring tons of cash to the bottom line: In Q3, it had $36 million in net income -- representing 45% of revenue. And as if this couldn't get any better, the company also generated $18 million in free cash flow in Q3.</p><p>In addition to this impressive profitability, the company has been able to consistently grow its top line at 76% year over year. It's not hard to see why shares trade at a staggering 184 times earnings and 36 times sales. However, this company has a dominant foothold in this market, with the majority of its consumer base on the platform, making advertising space nearly invaluable. This position has already led to growth and profitability, that I think could continue for the next decade.</p><h2>DermTech: A different approach to skin cancer</h2><p>DermTech is riskier than Doximity, but its growth potential is even larger. DermTech has created a new way to test for skin cancer that is easier, cheaper, and more accurate than the traditional biopsy. Instead of having a chunk of skin taken out, DermTech's PLA Test can simply be put on the area of concern like a bandage, and results are given within 72 hours. The chance of missing melanoma drops from 17% to 1% with DermTech.</p><p>Where DermTech has major growth potential is with its insurance coverage. While the company's product is not currently insured by the big insurance companies, it expects to obtain coverage in late 2022 or early 2023. If the company can get major insurance coverage, that could make it easier for doctors to switch over to its product.</p><p>Even without major coverage, the company is seeing impressive growth. Test revenue grew 140% year over year, and the company's sample volume reached 11,720, growing 75% year over year in Q3.</p><p>The company is nowhere near profitability, having lost almost seven times its revenue in Q3, but with just a $485 million market capitalization, it would be unrealistic to expect profitability at this stage. DermTech does, however, have over $204 million in cash and cash equivalents to subsidize its losses for some time. The company has only brought in $8.7 million in 2021, yet it has a market opportunity of over $10 billion. With such a large opportunity and a superior product, it is understandable that the company is valued at 40 times sales.</p><p>While its current valuation and unprofitability aren't appealing, the company could potentially grow its revenue by 100 times and still be scratching the surface of its addressable market. With this much potential, adding DermTech into a diversified portfolio could be a move that -- if it plays out -- could create portfolio-changing (and life-changing) results.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million? Buy and Hold These 2 Stocks for the Next Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million? Buy and Hold These 2 Stocks for the Next Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 16:16 GMT+8 <a href=https://www.fool.com/investing/2021/12/29/want-1-million-buy-and-hold-these-2-stocks-for-the/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market has had one of its best decades ever, with the SPDR S&P 500 ETF providing 275% returns over the past 10 years. While this performance is extremely impressive, I believe there are two ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/29/want-1-million-buy-and-hold-these-2-stocks-for-the/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","BK4539":"次新股","DOCS":"Doximity, Inc.","BK4139":"生物科技","BK4167":"医疗保健技术"},"source_url":"https://www.fool.com/investing/2021/12/29/want-1-million-buy-and-hold-these-2-stocks-for-the/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2195454191","content_text":"The stock market has had one of its best decades ever, with the SPDR S&P 500 ETF providing 275% returns over the past 10 years. While this performance is extremely impressive, I believe there are two stocks that could outperform the market and provide multibagger returns over the next decade.If you add Doximity (NYSE:DOCS) and DermTech (NASDAQ:DMTK) to a diversified portfolio, they could help you turn $100,000 into $1 million over the next decade. Here's how.Image source: Getty ImagesDoximity: A doctor's social mediaWhile many business professionals use Microsoft's LinkedIn, nearly 80% of medical professionals in the U.S. use Doximity. Doximity serves as a career growth app, a messaging app, an educational resource, and a social media platform all in one for doctors. In addition, Doximity offers telehealth accessibility, making it the super app for doctors and healthcare professionals.Doximity has truly become a primary platform that medical professionals use. Aside from the 80% of doctors on the platform, 50% of nurse practitioners and physician assistants use it, and a staggering 90% of medical students use it -- signaling that Doximity will continue to be the place where medical workers should go to collaborate, communicate, and expand their careers. As a result, Doximity's platform has attracted lots of advertisers.Doximity makes money from advertising revenue from pharmaceutical companies looking to show doctors their drugs on the research part of its app that delivers personalized news and research to doctors. Over 600 pharmaceutical companies are desperate to get their products in front of doctors and potential buyers, 200 of which spend over $100,000 per year to do so. What is most impressive is that Doximity's net retention rate is 173% -- meaning these customers spent 73 cents more in Q3 2021 on top of every dollar they spent in the year-ago quarter, including churning customers.In addition, 93% of Doximity's revenue comes from subscriptions from pharmaceutical companies. Because of this focus on subscriptions, its gross margins are a lofty 89%. Another factor making this company a financial powerhouse is the 80% share of U.S, doctors already on the platform, which means Doximity does not have to spend a ton on operating expenses. This allows for Doximity to bring tons of cash to the bottom line: In Q3, it had $36 million in net income -- representing 45% of revenue. And as if this couldn't get any better, the company also generated $18 million in free cash flow in Q3.In addition to this impressive profitability, the company has been able to consistently grow its top line at 76% year over year. It's not hard to see why shares trade at a staggering 184 times earnings and 36 times sales. However, this company has a dominant foothold in this market, with the majority of its consumer base on the platform, making advertising space nearly invaluable. This position has already led to growth and profitability, that I think could continue for the next decade.DermTech: A different approach to skin cancerDermTech is riskier than Doximity, but its growth potential is even larger. DermTech has created a new way to test for skin cancer that is easier, cheaper, and more accurate than the traditional biopsy. Instead of having a chunk of skin taken out, DermTech's PLA Test can simply be put on the area of concern like a bandage, and results are given within 72 hours. The chance of missing melanoma drops from 17% to 1% with DermTech.Where DermTech has major growth potential is with its insurance coverage. While the company's product is not currently insured by the big insurance companies, it expects to obtain coverage in late 2022 or early 2023. If the company can get major insurance coverage, that could make it easier for doctors to switch over to its product.Even without major coverage, the company is seeing impressive growth. Test revenue grew 140% year over year, and the company's sample volume reached 11,720, growing 75% year over year in Q3.The company is nowhere near profitability, having lost almost seven times its revenue in Q3, but with just a $485 million market capitalization, it would be unrealistic to expect profitability at this stage. DermTech does, however, have over $204 million in cash and cash equivalents to subsidize its losses for some time. The company has only brought in $8.7 million in 2021, yet it has a market opportunity of over $10 billion. With such a large opportunity and a superior product, it is understandable that the company is valued at 40 times sales.While its current valuation and unprofitability aren't appealing, the company could potentially grow its revenue by 100 times and still be scratching the surface of its addressable market. With this much potential, adding DermTech into a diversified portfolio could be a move that -- if it plays out -- could create portfolio-changing (and life-changing) results.","news_type":1,"symbols_score_info":{"DMTK":1,"DOCS":1}},"isVote":1,"tweetType":1,"viewCount":1708,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692368727,"gmtCreate":1640852241563,"gmtModify":1640852280593,"author":{"id":"3575018034770296","authorId":"3575018034770296","name":"AppleSeed","avatar":"https://static.tigerbbs.com/dd7084b7c374d1c9d55f5a6efe3e1115","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575018034770296","authorIdStr":"3575018034770296"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692368727","repostId":"2195468434","repostType":4,"repost":{"id":"2195468434","kind":"highlight","pubTimestamp":1640850220,"share":"https://ttm.financial/m/news/2195468434?lang=&edition=full","pubTime":"2021-12-30 15:43","market":"us","language":"en","title":"3 Rookie Mistakes to Avoid Making in the Stock Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2195468434","media":"Motley Fool","summary":"Now is a time to exercise more caution when picking stocks.","content":"<html><head></head><body><p>Both the pandemic as well as commission-free trading platforms like <b>Robinhood</b> have attracted a flurry of new investors into the stock market over the past couple of years. Retail investors have been playing a much larger role than ever before and have helped such meme stocks as <b>AMC Entertainment</b> and <b>GameStop</b> rally hundreds of percentage points at various times this year while the <b>S&P 500</b> has enjoyed a strong but much more modest gain of 28%.</p><p>Yet not everyone has become rich from investing in these risky stocks and trends. Many investors have lost big money betting on stocks. If you're a novice investor who has recently begun trading or are looking to get started investing in stocks next year, there are a few mistakes you'll want to avoid making. Here are three of the biggest ones that rookie investors make.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F658664%2Fpeople-playing-video-games-in-a-cafe_hUBfQy4.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><h2>1. Focusing too much on stock price</h2><p>Oftentimes when I talk to relatively new investors, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the things that comes up is a stock's price. But whether a stock is trading at $20, $200, or $2,000 is completely irrelevant. The more important question is the stock price in relation to the company's earnings -- known as its price-to-earnings (P/E) ratio. Investors might also look at the stock price in relation to the company's sales -- known as its price-to-sales multiple.</p><p>Consider tech giant <b>Amazon</b> (NASDAQ:AMZN), which trades at more than $3,400. That's a big number, but that alone doesn't mean it's an expensive stock. Amazon reported diluted earnings per share of about $51 over the trailing 12 months, so the stock is trading at around 67 times those earnings (and less than four times its revenue). That isn't cheap since the average stock in the <b>Technology Select Sector SPDR Fund </b>trades at only 34 times its profit. If Amazon's stock were to fall to a P/E of 34, its shares would still be worth more than $1,700 -- which again may look expensive -- but its valuation would now be in line with a typical tech stock.</p><p>Thus, looking solely at a stock's price without taking into context the company's underlying earnings or revenue should not be used to evaluate whether its shares are expensive.</p><h2>2. Focusing on the number of shares</h2><p>One thing a stock price can impact is how many shares you may end up owning. If you've got $10,000, you'll be able to buy roughly three shares of Amazon. But if you invested the same amount in tiny veterinarian health company <b>Zomedica </b>(NYSEMKT:ZOM), which trades at around $0.35, you could own more than 28,570 shares of the company.</p><p>In the end, it doesn't matter how many shares you own. It's the overall value of your investment that counts. A 10% increase in a $10,000 investment still represents a $1,000 profit, regardless of how many shares you own. So you want to be sure to own enough shares to meet your investment goal.</p><p>With Zomedica, you might be tempted to think that investing $100 in the stock is fine since you'll own about 285 shares of the company. But a $100 investment is still a $100 investment, regardless of your stock count. If you're spending the time to research stocks and find a good investment, make sure the investment is appropriately sized.</p><p>Of course, it's also important to consider the size of any individual investment in relation to your overall stock portfolio, making sure not to be overly concentrated in any one stock.</p><h2>3. Ignoring fundamentals</h2><p>If you don't spend much time researching and just feel as though you can risk taking a bet on the latest meme stock, that would be a big mistake as you could lose all your money. The fundamentals count.</p><p>Again, let's look at Zomedica, for example. This stock was popular with retail investors in the early part of the year, hitting a peak of $2.91 on Feb. 8. It has since fallen a mammoth 88%. Even if you bought it at just $1.00 a few months later, it would still be down more than 60% today -- a huge loss.</p><p>However, had you looked at the company's fundamentals before investing in its shares, you would have been aware of some significant risks. It was only in March that the company announced the first commercial sale of Truforma, its flagship product that helps veterinarians run diagnostics on animals. Through the first nine months of this year, the company has generated just $52,000 in revenue while incurring losses of more than $15 million.</p><p>So with an unproven product and a stock that is soaring for no clear reason, the writing was on the wall that this was an extremely risky investment. Lesson: Do your homework before you invest.</p><h2>Investors need to be more careful heading into 2022</h2><p>Although the S&P 500 has been having another strong year in 2021, with a new COVID-19 variant out there and interest rate increases on the horizon, next year could be a perilous one for the economy and stock market. So it's paramount that investors avoid big mistakes and make the best decisions they can with their money as 2022 approaches.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Rookie Mistakes to Avoid Making in the Stock Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Rookie Mistakes to Avoid Making in the Stock Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 15:43 GMT+8 <a href=https://www.fool.com/investing/2021/12/29/3-rookie-mistakes-to-avoid-making-in-the-stock-mar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Both the pandemic as well as commission-free trading platforms like Robinhood have attracted a flurry of new investors into the stock market over the past couple of years. Retail investors have been ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/29/3-rookie-mistakes-to-avoid-making-in-the-stock-mar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4527":"明星科技股",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","BK4534":"瑞士信贷持仓",".DJI":"道琼斯","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4503":"景林资产持仓","BK4122":"互联网与直销零售","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4538":"云计算","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","BK4507":"流媒体概念","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4532":"文艺复兴科技持仓","BK4561":"索罗斯持仓","BK4524":"宅经济概念","BK4554":"元宇宙及AR概念"},"source_url":"https://www.fool.com/investing/2021/12/29/3-rookie-mistakes-to-avoid-making-in-the-stock-mar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2195468434","content_text":"Both the pandemic as well as commission-free trading platforms like Robinhood have attracted a flurry of new investors into the stock market over the past couple of years. Retail investors have been playing a much larger role than ever before and have helped such meme stocks as AMC Entertainment and GameStop rally hundreds of percentage points at various times this year while the S&P 500 has enjoyed a strong but much more modest gain of 28%.Yet not everyone has become rich from investing in these risky stocks and trends. Many investors have lost big money betting on stocks. If you're a novice investor who has recently begun trading or are looking to get started investing in stocks next year, there are a few mistakes you'll want to avoid making. Here are three of the biggest ones that rookie investors make.Image source: Getty Images.1. Focusing too much on stock priceOftentimes when I talk to relatively new investors, one of the things that comes up is a stock's price. But whether a stock is trading at $20, $200, or $2,000 is completely irrelevant. The more important question is the stock price in relation to the company's earnings -- known as its price-to-earnings (P/E) ratio. Investors might also look at the stock price in relation to the company's sales -- known as its price-to-sales multiple.Consider tech giant Amazon (NASDAQ:AMZN), which trades at more than $3,400. That's a big number, but that alone doesn't mean it's an expensive stock. Amazon reported diluted earnings per share of about $51 over the trailing 12 months, so the stock is trading at around 67 times those earnings (and less than four times its revenue). That isn't cheap since the average stock in the Technology Select Sector SPDR Fund trades at only 34 times its profit. If Amazon's stock were to fall to a P/E of 34, its shares would still be worth more than $1,700 -- which again may look expensive -- but its valuation would now be in line with a typical tech stock.Thus, looking solely at a stock's price without taking into context the company's underlying earnings or revenue should not be used to evaluate whether its shares are expensive.2. Focusing on the number of sharesOne thing a stock price can impact is how many shares you may end up owning. If you've got $10,000, you'll be able to buy roughly three shares of Amazon. But if you invested the same amount in tiny veterinarian health company Zomedica (NYSEMKT:ZOM), which trades at around $0.35, you could own more than 28,570 shares of the company.In the end, it doesn't matter how many shares you own. It's the overall value of your investment that counts. A 10% increase in a $10,000 investment still represents a $1,000 profit, regardless of how many shares you own. So you want to be sure to own enough shares to meet your investment goal.With Zomedica, you might be tempted to think that investing $100 in the stock is fine since you'll own about 285 shares of the company. But a $100 investment is still a $100 investment, regardless of your stock count. If you're spending the time to research stocks and find a good investment, make sure the investment is appropriately sized.Of course, it's also important to consider the size of any individual investment in relation to your overall stock portfolio, making sure not to be overly concentrated in any one stock.3. Ignoring fundamentalsIf you don't spend much time researching and just feel as though you can risk taking a bet on the latest meme stock, that would be a big mistake as you could lose all your money. The fundamentals count.Again, let's look at Zomedica, for example. This stock was popular with retail investors in the early part of the year, hitting a peak of $2.91 on Feb. 8. It has since fallen a mammoth 88%. Even if you bought it at just $1.00 a few months later, it would still be down more than 60% today -- a huge loss.However, had you looked at the company's fundamentals before investing in its shares, you would have been aware of some significant risks. It was only in March that the company announced the first commercial sale of Truforma, its flagship product that helps veterinarians run diagnostics on animals. Through the first nine months of this year, the company has generated just $52,000 in revenue while incurring losses of more than $15 million.So with an unproven product and a stock that is soaring for no clear reason, the writing was on the wall that this was an extremely risky investment. Lesson: Do your homework before you invest.Investors need to be more careful heading into 2022Although the S&P 500 has been having another strong year in 2021, with a new COVID-19 variant out there and interest rate increases on the horizon, next year could be a perilous one for the economy and stock market. So it's paramount that investors avoid big mistakes and make the best decisions they can with their money as 2022 approaches.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":2892,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696710567,"gmtCreate":1640767107371,"gmtModify":1640767107540,"author":{"id":"3575018034770296","authorId":"3575018034770296","name":"AppleSeed","avatar":"https://static.tigerbbs.com/dd7084b7c374d1c9d55f5a6efe3e1115","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575018034770296","authorIdStr":"3575018034770296"},"themes":[],"htmlText":"Thank you and wishing everyone a prosperous 2022.","listText":"Thank you and wishing everyone a prosperous 2022.","text":"Thank you and wishing everyone a prosperous 2022.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696710567","isVote":1,"tweetType":1,"viewCount":1587,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691322508,"gmtCreate":1640139682406,"gmtModify":1640139682536,"author":{"id":"3575018034770296","authorId":"3575018034770296","name":"AppleSeed","avatar":"https://static.tigerbbs.com/dd7084b7c374d1c9d55f5a6efe3e1115","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575018034770296","authorIdStr":"3575018034770296"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691322508","repostId":"2193156023","repostType":2,"repost":{"id":"2193156023","kind":"highlight","pubTimestamp":1640092980,"share":"https://ttm.financial/m/news/2193156023?lang=&edition=full","pubTime":"2021-12-21 21:23","market":"us","language":"en","title":"5 Beaten-Down Growth Stocks That Can Soar in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2193156023","media":"Motley Fool","summary":"These high-flying stocks have all the tools necessary to regain their luster over the next year.","content":"<p>When the page turns on 2021 in just 10 days, it'll almost certainly go down as another successful year for the broad-market indexes. Through this past weekend, the benchmark <b>S&P 500</b> had gained 23% year to date, which is well above its historic average annual return.</p>\n<p>But it's been a bit of a mixed year for growth stocks. While the FAANG stocks have held up well, quite a few of the high-growth innovators that thrived during the pandemic were pummeled this year. If you're looking for high-quality, beaten-down growth stocks to invest in, the following five could soar in 2022.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F658086%2Fanalyzing-stock-market-growth-chart-getty.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"464\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Nio</h2>\n<p>Once an electric vehicle (EV) darling on Wall Street, China-based EV manufacturer <b>Nio</b> (NYSE:NIO) lost its charge this year. Through Dec. 19, shares of the company were lower by 38%.</p>\n<p>Nio has been plagued for roughly half the year by supply chain issues (specifically semiconductor chip shortages) tied to the pandemic. However, with these supply issues beginning to resolve, Nio has a clear path to quickly boost its EV output and perhaps even push toward recurring profitability by the end of next year.</p>\n<p>In November, we received a pretty big clue that supply chain issues weren't holding the company back any longer. Deliveries for the month hit 10,878, which works out to more than 130,000 EVs on an annual run rate basis. With the company aiming to introduce three new vehicles next year, as well as lift its annual run rate to 600,000 EVs by year's end, Nio's shares could well be electric.</p>\n<p>Furthermore, don't overlook the importance of its battery-as-a-service (BaaS) program, which allows EV buyers to charge, swap, and upgrade their batteries. The BaaS service charges a recurring monthly fee and reduces the initial purchase price of Nio EVs. In exchange for giving up near-term revenue, the BaaS program will secure high-margin, long-term, fee-based revenue, and it'll provide added incentive for buyers to remain loyal to the Nio brand for a long time to come.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F658086%2Fwoman-testing-server-data-center-network-wireless-iot-business-getty.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Fastly</h2>\n<p>Edge cloud services provider <b>Fastly</b> (NYSE:FSLY) has been something of a train wreck in 2021. As of this past weekend, shares were lower by 53%, year to date.</p>\n<p>Fastly's woes are the result of bigger-than-expected operating losses as headcount and marketing expenses ramped up, as well as a service outage in June that caused the company to lose a handful of customers. Though the luster may be temporarily removed from this pandemic highflier, the long-term growth thesis remains firmly in place.</p>\n<p>Fastly is arguably best known as a content delivery network specialist. Its job is to ensure that content reaches end users as quickly and securely as possible. To that end, adjusted gross margin continues to hover around a juicy 60% (plus or minus 3%), and the company's total customer count keeps heading higher. With few exceptions, existing clients are consistently increasing their spending by a double-digit percentage on a year-over-year basis.</p>\n<p>Fastly also happens to be a clear and obvious beneficiary of growth in the metaverse -- the next iteration of the internet that allows users to interact in 3D virtual environments. One of the most critical aspects of making the metaverse tick will be reducing latency. In other words, minimizing lag in data-driven virtual worlds will be key, and Fastly should be up to the task.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F658086%2Fcannabis-plant-marijuana-pot-weed-dried-flower-legal-canada-us-getty.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Cresco Labs</h2>\n<p>Marijuana stocks started 2021 with a bang, but they've been an utter buzzkill since February. This is especially true for U.S. multi-state operator (MSO) <b>Cresco Labs</b> (OTC:CRLBF), whose shares have fallen 32% this year.</p>\n<p>Cannabis stocks like Cresco bolted higher earlier this year on the idea that newly elected President Joe Biden and a Democrat-led Congress would legalize pot at the federal level, or at worst pass cannabis banking reforms. Unfortunately, none of this has come to fruition and pot stock investors watched their early-year gains go up in smoke. Thankfully, federal legalization isn't a requirement for large-scale MSOs to thrive.</p>\n<p>Cresco currently has 45 operating dispensaries, with many focused on high-dollar markets (Florida) or limited-license states (like Illinois and Ohio). Regulators in limited-license markets purposely cap the number of dispensary licenses issued in total, as well as to a single business. Since Cresco doesn't have a huge retail presence, this license limitation actually works in its favor. It's able to build up its brands and garner a loyal following without being overrun by a larger MSO.</p>\n<p>What's more, Cresco Labs is the industry leader in wholesale cannabis. It holds a coveted cannabis distribution license in California, the leading market for weed sales in the world. This license allows the company to place its proprietary pot products into more than 575 dispensaries throughout the Golden State. Wholesale could be Cresco's key to reaching recurring profitability in 2022.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F658086%2Ftelemedicine-patient-doctor-physician-virtual-conference-healthcare-getty.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Teladoc Health</h2>\n<p>Another popular pandemic play that's been beaten down in 2021 is <b>Teladoc Health</b> (NYSE:TDOC). The United States' leading telehealth provider has seen shares dive 51% this year, and at <a href=\"https://laohu8.com/S/AONE.U\">one</a> point they fell more than 70% from their February 2021 all-time high.</p>\n<p>The concerns with Teladoc center on its wider-than-expected losses following the acquisition of applied health signals company Livongo Health, as well as skepticism that its growth rates are sustainable with the worst of the coronavirus pandemic (perhaps) in the rearview mirror. However, neither of these issues disrupts or alters the long-term thesis for Teladoc.</p>\n<p>For instance, Teladoc is completely changing the way personalized care is administered in the United States. It's offering a more convenient way for patients and doctors to connect, and making it much easier for physicians to keep tabs on chronically ill people. Ultimately, virtual visits can improve patient outcomes and lower healthcare costs, which is music to the ears of health insurers. Perhaps this is why Teladoc averaged 74% annual revenue growth in the six years leading up to the pandemic.</p>\n<p>The buyout of Livongo is also a key differentiator. Livongo leans on artificial intelligence to send tips and nudges to people with chronic illnesses to help them lead healthier lives. Thus far, it's primarily been focused on people with diabetes. Looking ahead, Livongo will target its services to include those with hypertension and weight management issues. Teladoc and Livongo being able to cross-sell their services should make this among the fastest-growing healthcare companies this decade.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F658086%2Fwork-from-home-laptop-businesswoman-wheelchair-coffee-getty.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Pinterest</h2>\n<p>A fifth beaten-down growth stock with the potential to soar in 2022 is social media platform <b>Pinterest</b> (NYSE:PINS). Shares are down nearly 45% this year, as of last weekend.</p>\n<p>Pinterest's miserable performance in 2021 can be explained by its monthly active user (MAU) figures. After delivering blistering MAU growth throughout the pandemic, the company's second-quarter and third-quarter MAU figures have sequentially declined. This drop from a peak of 478 million MAUs at the end of the first quarter to 444 million MAUs by the end of Q3 hasn't sat well with Wall Street.</p>\n<p>But there's another side to this story. Reset the binoculars to look at MAU growth over the past four or five years, and you'll see that user growth is still within historic norms. More importantly, Pinterest is generating incredible sales growth from monetizing its user base. Even though MAUs increased less than 1% in the third quarter, average revenue per user (ARPU) globally rose 37%, with international ARPU skyrocketing 81% from the prior-year period. This plainly shows that advertisers will pay big bucks to get their message in front of Pinterest's users.</p>\n<p>There's also a clear path for Pinterest to become a force in e-commerce this decade. Since its users freely post about the things, places, and services that interest them, there's no guesswork as to what they like. This allows merchants to effectively target their ad dollars at motivated shoppers. As long as Pinterest can keep users engaged, it'll be the perfect e-commerce middleman.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Beaten-Down Growth Stocks That Can Soar in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Beaten-Down Growth Stocks That Can Soar in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 21:23 GMT+8 <a href=https://www.fool.com/investing/2021/12/21/5-beaten-down-growth-stocks-that-can-soar-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When the page turns on 2021 in just 10 days, it'll almost certainly go down as another successful year for the broad-market indexes. Through this past weekend, the benchmark S&P 500 had gained 23% ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/21/5-beaten-down-growth-stocks-that-can-soar-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4077":"互动媒体与服务","BK4116":"互联网服务与基础架构","BK4531":"中概回港概念","BK4099":"汽车制造商","BK4526":"热门中概股","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","TDOC":"Teladoc Health Inc.","BK4555":"新能源车","PINS":"Pinterest, Inc.","BK4505":"高瓴资本持仓","BK4167":"医疗保健技术","BK4504":"桥水持仓","NIO":"蔚来","FSLY":"Fastly, Inc.","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4509":"腾讯概念","BK4508":"社交媒体","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓"},"source_url":"https://www.fool.com/investing/2021/12/21/5-beaten-down-growth-stocks-that-can-soar-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193156023","content_text":"When the page turns on 2021 in just 10 days, it'll almost certainly go down as another successful year for the broad-market indexes. Through this past weekend, the benchmark S&P 500 had gained 23% year to date, which is well above its historic average annual return.\nBut it's been a bit of a mixed year for growth stocks. While the FAANG stocks have held up well, quite a few of the high-growth innovators that thrived during the pandemic were pummeled this year. If you're looking for high-quality, beaten-down growth stocks to invest in, the following five could soar in 2022.\nImage source: Getty Images.\nNio\nOnce an electric vehicle (EV) darling on Wall Street, China-based EV manufacturer Nio (NYSE:NIO) lost its charge this year. Through Dec. 19, shares of the company were lower by 38%.\nNio has been plagued for roughly half the year by supply chain issues (specifically semiconductor chip shortages) tied to the pandemic. However, with these supply issues beginning to resolve, Nio has a clear path to quickly boost its EV output and perhaps even push toward recurring profitability by the end of next year.\nIn November, we received a pretty big clue that supply chain issues weren't holding the company back any longer. Deliveries for the month hit 10,878, which works out to more than 130,000 EVs on an annual run rate basis. With the company aiming to introduce three new vehicles next year, as well as lift its annual run rate to 600,000 EVs by year's end, Nio's shares could well be electric.\nFurthermore, don't overlook the importance of its battery-as-a-service (BaaS) program, which allows EV buyers to charge, swap, and upgrade their batteries. The BaaS service charges a recurring monthly fee and reduces the initial purchase price of Nio EVs. In exchange for giving up near-term revenue, the BaaS program will secure high-margin, long-term, fee-based revenue, and it'll provide added incentive for buyers to remain loyal to the Nio brand for a long time to come.\nImage source: Getty Images.\nFastly\nEdge cloud services provider Fastly (NYSE:FSLY) has been something of a train wreck in 2021. As of this past weekend, shares were lower by 53%, year to date.\nFastly's woes are the result of bigger-than-expected operating losses as headcount and marketing expenses ramped up, as well as a service outage in June that caused the company to lose a handful of customers. Though the luster may be temporarily removed from this pandemic highflier, the long-term growth thesis remains firmly in place.\nFastly is arguably best known as a content delivery network specialist. Its job is to ensure that content reaches end users as quickly and securely as possible. To that end, adjusted gross margin continues to hover around a juicy 60% (plus or minus 3%), and the company's total customer count keeps heading higher. With few exceptions, existing clients are consistently increasing their spending by a double-digit percentage on a year-over-year basis.\nFastly also happens to be a clear and obvious beneficiary of growth in the metaverse -- the next iteration of the internet that allows users to interact in 3D virtual environments. One of the most critical aspects of making the metaverse tick will be reducing latency. In other words, minimizing lag in data-driven virtual worlds will be key, and Fastly should be up to the task.\nImage source: Getty Images.\nCresco Labs\nMarijuana stocks started 2021 with a bang, but they've been an utter buzzkill since February. This is especially true for U.S. multi-state operator (MSO) Cresco Labs (OTC:CRLBF), whose shares have fallen 32% this year.\nCannabis stocks like Cresco bolted higher earlier this year on the idea that newly elected President Joe Biden and a Democrat-led Congress would legalize pot at the federal level, or at worst pass cannabis banking reforms. Unfortunately, none of this has come to fruition and pot stock investors watched their early-year gains go up in smoke. Thankfully, federal legalization isn't a requirement for large-scale MSOs to thrive.\nCresco currently has 45 operating dispensaries, with many focused on high-dollar markets (Florida) or limited-license states (like Illinois and Ohio). Regulators in limited-license markets purposely cap the number of dispensary licenses issued in total, as well as to a single business. Since Cresco doesn't have a huge retail presence, this license limitation actually works in its favor. It's able to build up its brands and garner a loyal following without being overrun by a larger MSO.\nWhat's more, Cresco Labs is the industry leader in wholesale cannabis. It holds a coveted cannabis distribution license in California, the leading market for weed sales in the world. This license allows the company to place its proprietary pot products into more than 575 dispensaries throughout the Golden State. Wholesale could be Cresco's key to reaching recurring profitability in 2022.\nImage source: Getty Images.\nTeladoc Health\nAnother popular pandemic play that's been beaten down in 2021 is Teladoc Health (NYSE:TDOC). The United States' leading telehealth provider has seen shares dive 51% this year, and at one point they fell more than 70% from their February 2021 all-time high.\nThe concerns with Teladoc center on its wider-than-expected losses following the acquisition of applied health signals company Livongo Health, as well as skepticism that its growth rates are sustainable with the worst of the coronavirus pandemic (perhaps) in the rearview mirror. However, neither of these issues disrupts or alters the long-term thesis for Teladoc.\nFor instance, Teladoc is completely changing the way personalized care is administered in the United States. It's offering a more convenient way for patients and doctors to connect, and making it much easier for physicians to keep tabs on chronically ill people. Ultimately, virtual visits can improve patient outcomes and lower healthcare costs, which is music to the ears of health insurers. Perhaps this is why Teladoc averaged 74% annual revenue growth in the six years leading up to the pandemic.\nThe buyout of Livongo is also a key differentiator. Livongo leans on artificial intelligence to send tips and nudges to people with chronic illnesses to help them lead healthier lives. Thus far, it's primarily been focused on people with diabetes. Looking ahead, Livongo will target its services to include those with hypertension and weight management issues. Teladoc and Livongo being able to cross-sell their services should make this among the fastest-growing healthcare companies this decade.\nImage source: Getty Images.\nPinterest\nA fifth beaten-down growth stock with the potential to soar in 2022 is social media platform Pinterest (NYSE:PINS). Shares are down nearly 45% this year, as of last weekend.\nPinterest's miserable performance in 2021 can be explained by its monthly active user (MAU) figures. After delivering blistering MAU growth throughout the pandemic, the company's second-quarter and third-quarter MAU figures have sequentially declined. This drop from a peak of 478 million MAUs at the end of the first quarter to 444 million MAUs by the end of Q3 hasn't sat well with Wall Street.\nBut there's another side to this story. Reset the binoculars to look at MAU growth over the past four or five years, and you'll see that user growth is still within historic norms. More importantly, Pinterest is generating incredible sales growth from monetizing its user base. Even though MAUs increased less than 1% in the third quarter, average revenue per user (ARPU) globally rose 37%, with international ARPU skyrocketing 81% from the prior-year period. This plainly shows that advertisers will pay big bucks to get their message in front of Pinterest's users.\nThere's also a clear path for Pinterest to become a force in e-commerce this decade. Since its users freely post about the things, places, and services that interest them, there's no guesswork as to what they like. This allows merchants to effectively target their ad dollars at motivated shoppers. As long as Pinterest can keep users engaged, it'll be the perfect e-commerce middleman.","news_type":1,"symbols_score_info":{"FSLY":0.9,"MSO":0.9,"NIO":0.9,"PINS":0.9,"TDOC":0.9}},"isVote":1,"tweetType":1,"viewCount":1742,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604897653,"gmtCreate":1639366497264,"gmtModify":1639366497379,"author":{"id":"3575018034770296","authorId":"3575018034770296","name":"AppleSeed","avatar":"https://static.tigerbbs.com/dd7084b7c374d1c9d55f5a6efe3e1115","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575018034770296","authorIdStr":"3575018034770296"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604897653","repostId":"2191708046","repostType":4,"repost":{"id":"2191708046","kind":"news","pubTimestamp":1639366317,"share":"https://ttm.financial/m/news/2191708046?lang=&edition=full","pubTime":"2021-12-13 11:31","market":"us","language":"en","title":"Charlie Munger: This market is 'even crazier' than the dot-com bust — here are 3 contrarian stocks to help you sidestep the herd","url":"https://stock-news.laohu8.com/highlight/detail?id=2191708046","media":"MoneyWise","summary":"Berkshire Hathaway Vice Chairman Charlie Munger tends to be much more direct with his warnings and c","content":"<p><img src=\"https://static.tigerbbs.com/5664762597a5b9b6b53168b267173a39\" tg-width=\"1800\" tg-height=\"800\" referrerpolicy=\"no-referrer\"></p>\n<p>Berkshire Hathaway Vice Chairman Charlie Munger tends to be much more direct with his warnings and criticisms than his business partner, Warren Buffett.</p>\n<p>Munger didn’t mince words when he said earlier this month that he considers today’s stock market environment “even crazier than the dot-com era.”</p>\n<p>\"I just can't stand participating in these insane booms,” Munger said at the Sohn Hearts & Minds Investment Leaders Conference. “There's no great company that can't be turned into a bad investment just by raising the price.\"</p>\n<p>Munger, as usual, had harsh words for cryptocurrencies. He praised China’s crackdown on crypto and said he wished the technology “had never been invented.”</p>\n<p>One way to avoid both crypto and getting burned by an overvalued market is to look at companies with stock that has dropped but seems poised for a rebound.</p>\n<p>Here are three stocks with some bruises that fit that category. You might even be able to include some undervalued stocks in your portfolio with a little spare change.</p>\n<h2>Walt Disney Co. (DIS)</h2>\n<p><img src=\"https://static.tigerbbs.com/1eb7ad7f596bcaa16827853ace850b05\" tg-width=\"1200\" tg-height=\"500\" referrerpolicy=\"no-referrer\">AFM Visuals/Shutterstock</p>\n<p>Disney’s stock got hammered in the pandemic’s early days, shedding about 38% of its value in the month ending March 20, 2020. After rallying for much of last year, it’s down almost 15% since the beginning of 2021. Disney’s earnings in the fiscal fourth quarter, which ended Oct. 2, came in about $200 million short of expectations. Its theme parks are still operating at reduced capacity, so Q4’s results could have been much worse.</p>\n<p>Streaming platform Disney+ is up to 118.1 million subscribers, and the company projects that figure will grow to more than 230 million by 2024. While the company says Disney+ subscriber growth slowed, revenue from subscriptions across Disney+, ESPN+ and Hulu was $4.6 billion in Q4 — 38% higher than a year before.</p>\n<p>Disney remains a beloved global brand and says it expects international visitors to parks to pick up later in 2022 as restrictions ease. JPMorgan Chase predicts a full economic rebound from COVID-19 in 2022, and if that’s true, Disney’s theme parks could once again be packed.</p>\n<h2>Mastercard (MA)</h2>\n<p><img src=\"https://static.tigerbbs.com/aed78bfcce51f38789bf91a87e4815ed\" tg-width=\"1200\" tg-height=\"500\" referrerpolicy=\"no-referrer\">garmoncheg/Shutterstock</p>\n<p>Mastercard’s stock has been mostly trending downward since July, and it recently hit the skids, shrinking by 17% from Nov. 16 through Dec. 1. However, it’s trending upward over the last week or so, recovering most of that recent loss.</p>\n<p>The sell-off of Mastercard’s stock doesn’t appear to have anything to do with the company’s performance. Q3 net revenue was $5 billion, a year-over-year increase of 30%. Purchase volume was up 23% over the same period.</p>\n<p>Mastercard’s in a tricky position. Buy now, pay later apps are doing their best to disrupt the credit card space, and the company doesn’t currently seem to have an answer that will help increase the company’s cache with younger users.</p>\n<p>But that could be more of a long-term issue. In the short-term, inflation-jacked prices mean customers are paying more, and a rebound in tourism and credit card spending should have the company’s users — there’s almost a billion of them — ringing up purchases left and right.</p>\n<h2>AT&T (T)</h2>\n<p><img src=\"https://static.tigerbbs.com/2584b9217af4e8f8876958e9a7bf34a2\" tg-width=\"1200\" tg-height=\"500\" referrerpolicy=\"no-referrer\">Jonathan Weiss/Shutterstock</p>\n<p>AT&T’s stock has been on a downward tumble for a while now. Its share price is 45% lower than it was five years ago, and is down more than 22% this year alone.</p>\n<p>AT&T has taken some big swings that haven’t paid off. Its purchase of DirecTV and Time Warner in 2015 and 2018, respectively, added more than $130 billion in debt to the company’s balance sheet. Last year, T-Mobile replaced AT&T as America’s second-largest wireless carrier.</p>\n<p>None of that sounds particularly enticing, but the company knows changes need to be made. It divested a number of its smaller businesses and some of its real estate holdings and sold 30% of DirecTV to streamline operations and free up capital for the expansion of its 5G network, which could be huge.</p>\n<p>AT&T is still a risky buy with its stumbles this year, but if you believe in the turnaround plan, the anxiety might be worthwhile. Big picture, AT&T continues to boast the scale advantages required to compete in the high-growth wireless space long term.</p>\n<h2>If your faith in the market is flagging …</h2>\n<p><img src=\"https://static.tigerbbs.com/eedd4d7004b766d5dc2e8fe34b4c1922\" tg-width=\"1200\" tg-height=\"500\" referrerpolicy=\"no-referrer\">MartinLueke/Shutterstock</p>\n<p>With elite investors like Charlie Munger, Michael Burry and Jeremy Grantham all saying the market is due for a correction, it might be worth looking into investments other than stocks.</p>\n<p>There’s no shortage of unique alternative assets you can invest in that have little correlation with the stock market, including luxury vehicles, commercial real estate, blue-chip artworks or even marine finance.</p>\n<p>Traditionally, many alternative asset classes have only been available to millionaires because of the enormous costs involved. But a new platform is making these opportunities available to retail investors too.</p>\n<p><i>This article provides information only and should not be construed as advice. It is provided without warranty of any kind.</i></p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Charlie Munger: This market is 'even crazier' than the dot-com bust — here are 3 contrarian stocks to help you sidestep the herd</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCharlie Munger: This market is 'even crazier' than the dot-com bust — here are 3 contrarian stocks to help you sidestep the herd\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:31 GMT+8 <a href=https://finance.yahoo.com/news/charlie-munger-market-even-crazier-164000236.html><strong>MoneyWise</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway Vice Chairman Charlie Munger tends to be much more direct with his warnings and criticisms than his business partner, Warren Buffett.\nMunger didn’t mince words when he said earlier ...</p>\n\n<a href=\"https://finance.yahoo.com/news/charlie-munger-market-even-crazier-164000236.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4566":"资本集团","BK4106":"数据处理与外包服务","BK4535":"淡马锡持仓","BK4515":"5G概念","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","BK4108":"电影和娱乐","BK4548":"巴美列捷福持仓","BK4507":"流媒体概念","BK4551":"寇图资本持仓","BK4561":"索罗斯持仓","BK4554":"元宇宙及AR概念","DIS":"迪士尼","BK4524":"宅经济概念","BK4532":"文艺复兴科技持仓","MA":"万事达","T":"At&T","BK4527":"明星科技股","BK4534":"瑞士信贷持仓","BK4115":"综合电信业务","BK4533":"AQR资本管理(全球第二大对冲基金)"},"source_url":"https://finance.yahoo.com/news/charlie-munger-market-even-crazier-164000236.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2191708046","content_text":"Berkshire Hathaway Vice Chairman Charlie Munger tends to be much more direct with his warnings and criticisms than his business partner, Warren Buffett.\nMunger didn’t mince words when he said earlier this month that he considers today’s stock market environment “even crazier than the dot-com era.”\n\"I just can't stand participating in these insane booms,” Munger said at the Sohn Hearts & Minds Investment Leaders Conference. “There's no great company that can't be turned into a bad investment just by raising the price.\"\nMunger, as usual, had harsh words for cryptocurrencies. He praised China’s crackdown on crypto and said he wished the technology “had never been invented.”\nOne way to avoid both crypto and getting burned by an overvalued market is to look at companies with stock that has dropped but seems poised for a rebound.\nHere are three stocks with some bruises that fit that category. You might even be able to include some undervalued stocks in your portfolio with a little spare change.\nWalt Disney Co. (DIS)\nAFM Visuals/Shutterstock\nDisney’s stock got hammered in the pandemic’s early days, shedding about 38% of its value in the month ending March 20, 2020. After rallying for much of last year, it’s down almost 15% since the beginning of 2021. Disney’s earnings in the fiscal fourth quarter, which ended Oct. 2, came in about $200 million short of expectations. Its theme parks are still operating at reduced capacity, so Q4’s results could have been much worse.\nStreaming platform Disney+ is up to 118.1 million subscribers, and the company projects that figure will grow to more than 230 million by 2024. While the company says Disney+ subscriber growth slowed, revenue from subscriptions across Disney+, ESPN+ and Hulu was $4.6 billion in Q4 — 38% higher than a year before.\nDisney remains a beloved global brand and says it expects international visitors to parks to pick up later in 2022 as restrictions ease. JPMorgan Chase predicts a full economic rebound from COVID-19 in 2022, and if that’s true, Disney’s theme parks could once again be packed.\nMastercard (MA)\ngarmoncheg/Shutterstock\nMastercard’s stock has been mostly trending downward since July, and it recently hit the skids, shrinking by 17% from Nov. 16 through Dec. 1. However, it’s trending upward over the last week or so, recovering most of that recent loss.\nThe sell-off of Mastercard’s stock doesn’t appear to have anything to do with the company’s performance. Q3 net revenue was $5 billion, a year-over-year increase of 30%. Purchase volume was up 23% over the same period.\nMastercard’s in a tricky position. Buy now, pay later apps are doing their best to disrupt the credit card space, and the company doesn’t currently seem to have an answer that will help increase the company’s cache with younger users.\nBut that could be more of a long-term issue. In the short-term, inflation-jacked prices mean customers are paying more, and a rebound in tourism and credit card spending should have the company’s users — there’s almost a billion of them — ringing up purchases left and right.\nAT&T (T)\nJonathan Weiss/Shutterstock\nAT&T’s stock has been on a downward tumble for a while now. Its share price is 45% lower than it was five years ago, and is down more than 22% this year alone.\nAT&T has taken some big swings that haven’t paid off. Its purchase of DirecTV and Time Warner in 2015 and 2018, respectively, added more than $130 billion in debt to the company’s balance sheet. Last year, T-Mobile replaced AT&T as America’s second-largest wireless carrier.\nNone of that sounds particularly enticing, but the company knows changes need to be made. It divested a number of its smaller businesses and some of its real estate holdings and sold 30% of DirecTV to streamline operations and free up capital for the expansion of its 5G network, which could be huge.\nAT&T is still a risky buy with its stumbles this year, but if you believe in the turnaround plan, the anxiety might be worthwhile. Big picture, AT&T continues to boast the scale advantages required to compete in the high-growth wireless space long term.\nIf your faith in the market is flagging …\nMartinLueke/Shutterstock\nWith elite investors like Charlie Munger, Michael Burry and Jeremy Grantham all saying the market is due for a correction, it might be worth looking into investments other than stocks.\nThere’s no shortage of unique alternative assets you can invest in that have little correlation with the stock market, including luxury vehicles, commercial real estate, blue-chip artworks or even marine finance.\nTraditionally, many alternative asset classes have only been available to millionaires because of the enormous costs involved. But a new platform is making these opportunities available to retail investors too.\nThis article provides information only and should not be construed as advice. It is provided without warranty of any kind.","news_type":1,"symbols_score_info":{"DIS":0.9,"MA":0.9,"T":0.9}},"isVote":1,"tweetType":1,"viewCount":2492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604901483,"gmtCreate":1639294534843,"gmtModify":1639294534965,"author":{"id":"3575018034770296","authorId":"3575018034770296","name":"AppleSeed","avatar":"https://static.tigerbbs.com/dd7084b7c374d1c9d55f5a6efe3e1115","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575018034770296","authorIdStr":"3575018034770296"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/604901483","repostId":"2190967197","repostType":4,"repost":{"id":"2190967197","kind":"highlight","pubTimestamp":1639273902,"share":"https://ttm.financial/m/news/2190967197?lang=&edition=full","pubTime":"2021-12-12 09:51","market":"us","language":"en","title":"At Its Highest Price in a Decade, Can Bank of America Go Higher in 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=2190967197","media":"Motley Fool","summary":"The bank now trades at a strong valuation but also has a good outlook for 2022.","content":"<p>What a year it's been for <b>Bank of America</b> (NYSE:BAC). The stock price is up 47% this year and is more than double the lows it hit at the very beginning of the pandemic. At about $44 per share, the stock is at its highest level in more than a decade. Warren Buffett knew what he was doing when he plowed more than $2 billion into the stock in mid-2020. With a premium valuation, can America's second-largest bank by assets go higher in 2022? Let's take a look.</p>\n<h2>What to expect in 2022</h2>\n<p>This year's earnings at most banks were lumpy, with billions in reserves being released after previously being built up to manage loan losses that didn't materialize. Banks also generated record revenue for investment banking and sales and trading, but then saw slacking loan growth in the extremely low-rate environment.</p>\n<p><img src=\"https://static.tigerbbs.com/4362e920486edd2b13dc87efb01af483\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Bank of America.</p>\n<p>That's why analysts' consensus earnings per share (EPS) estimate for Bank of America in 2022 is $3.17, down from the $3.51 expected this year. But while EPS is estimated to shrink, Bank of America's revenue is projected by analysts to grow from just shy of $90 billion this year to more than $94 billion in 2022. The releasing of billions of dollars of reserves this year artificially juiced earnings after a tough year in 2020, so that will likely go away as loan balances start to tick up, which inevitably requires banks to stash away reserve capital for the normal course of losses expected over the life of a loan portfolio.</p>\n<p>However, with inflation now very real, Bank of America's research team sees the Federal Reserve hiking its federal funds rate three times in 2022. It's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most asset-sensitive banks in the country, meaning the yields on more of its interest-earning assets such as loans will reprice higher than yields on its interest-bearing deposits like liabilities.</p>\n<p>In its third-quarter presentation, Bank of America management noted that a 1% parallel move in short- and long-term yields would result in more than $7 billion of net interest income over the next year. Assuming three rate hikes, the bank will get a lot of that added net interest income. And who knows: If loan growth can pick up, that could boost net interest income more.</p>\n<p>The outlook for investment banking and sales and trading is also likely improving for 2022. After phenomenal performances in 2020 and early 2021, many thought these lines of business, which tend to thrive during periods of volatility, might settle down -- and fixed-income, currencies, and commodities trading has slowed from record levels seen earlier this year.</p>\n<p>But <b>JPMorgan Chase</b> analysts released a research note in October that said as inflation gets higher and bond yields creep up, that will likely create more volatility in the markets, which is when trading can pick up because there is less liquidity. With the Fed speeding up the tapering of its bond-buying program, this will also reduce the amount of liquidity in the market.</p>\n<p>Also, Bank of America is coming off a strong year in investment banking with lots of mergers and acquisitions activity. In multiple quarters this year, Bank of America generated more than $2 billion in investment banking fees, which was near record levels. CEO Brian Moynihan said at a recent conference that he thinks the team can get another quarter topping $2 billion in the future.</p>\n<p>With a bullish outlook in so many of Bank of America's business lines, and considering that the bank is currently buying back a lot of stock, I am optimistic that 2022 can be another strong year for earnings.</p>\n<h2>How to value the stock</h2>\n<p>Banks trade relative to their earnings and also to their tangible book value (TBV), which is what a bank would be worth if it were liquidated.</p>\n<p><img src=\"https://static.tigerbbs.com/0e7815935a2d177dc95dc4356740046f\" tg-width=\"720\" tg-height=\"449\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>BAC P/E ratio data by YCharts.</p>\n<p>Over the past five years or so, Bank of America has traded in a range of about 7 times earnings to close to 20 times earnings. Most large banks trade in the 11-to-14 window. Its price-to-tangible book has ranged from around 100% to 200%, and 200% is certainly a strong price-to-TBV ratio in this low-rate environment.</p>\n<p>But Bank of America, in my opinion, is in the strongest position it's ever been in. The bank has significantly enhanced its corporate and investment banking division, improved its deposit base, and continues to be a dominant commercial lender. Its digital capabilities are much better now as well, which will pay off as the pandemic has accelerated digital banking trends.</p>\n<p>Banks also solved a huge reputational issue during the pandemic that has dogged them since the Great Recession. They escaped a significant and rapid downturn with superb credit quality and were part of the solution this time around instead of the main issue behind the meltdown. Because banks looked so bad coming out of the Great Recession, I think investors have been very wary to return to them.</p>\n<p>For all of these reasons, it wouldn't be unreasonable for the bank to trade at an earnings multiple in the upper echelon of its previous range. While some of the benefits of rate hikes have been priced in, I think a large-cap bank stock like Bank of America could trade at 15 times earnings, which it traded around the last time rates rose in 2017 and 2018. With EPS estimated at $3.17 in 2022, that implies a share price of $47.55, which does not imply a ton of upside from the current stock price.</p>\n<p>Again, some of the benefits I've discussed from higher rates are likely priced in, but those earnings estimates from analysts for 2022 could certainly be conservative, so there could be further upside as well.</p>\n<p>Are there higher-growth opportunities elsewhere? Probably. But on a much longer-term basis, I have all the confidence in the world that Bank of America can keep delivering strong and consistent returns for investors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>At Its Highest Price in a Decade, Can Bank of America Go Higher in 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAt Its Highest Price in a Decade, Can Bank of America Go Higher in 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-12 09:51 GMT+8 <a href=https://www.fool.com/investing/2021/12/11/trading-high-price-decade-bank-of-america-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What a year it's been for Bank of America (NYSE:BAC). The stock price is up 47% this year and is more than double the lows it hit at the very beginning of the pandemic. At about $44 per share, the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/11/trading-high-price-decade-bank-of-america-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4553":"喜马拉雅资本持仓","BK4207":"综合性银行","BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","BAC":"美国银行","BK4559":"巴菲特持仓"},"source_url":"https://www.fool.com/investing/2021/12/11/trading-high-price-decade-bank-of-america-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190967197","content_text":"What a year it's been for Bank of America (NYSE:BAC). The stock price is up 47% this year and is more than double the lows it hit at the very beginning of the pandemic. At about $44 per share, the stock is at its highest level in more than a decade. Warren Buffett knew what he was doing when he plowed more than $2 billion into the stock in mid-2020. With a premium valuation, can America's second-largest bank by assets go higher in 2022? Let's take a look.\nWhat to expect in 2022\nThis year's earnings at most banks were lumpy, with billions in reserves being released after previously being built up to manage loan losses that didn't materialize. Banks also generated record revenue for investment banking and sales and trading, but then saw slacking loan growth in the extremely low-rate environment.\n\nImage source: Bank of America.\nThat's why analysts' consensus earnings per share (EPS) estimate for Bank of America in 2022 is $3.17, down from the $3.51 expected this year. But while EPS is estimated to shrink, Bank of America's revenue is projected by analysts to grow from just shy of $90 billion this year to more than $94 billion in 2022. The releasing of billions of dollars of reserves this year artificially juiced earnings after a tough year in 2020, so that will likely go away as loan balances start to tick up, which inevitably requires banks to stash away reserve capital for the normal course of losses expected over the life of a loan portfolio.\nHowever, with inflation now very real, Bank of America's research team sees the Federal Reserve hiking its federal funds rate three times in 2022. It's one of the most asset-sensitive banks in the country, meaning the yields on more of its interest-earning assets such as loans will reprice higher than yields on its interest-bearing deposits like liabilities.\nIn its third-quarter presentation, Bank of America management noted that a 1% parallel move in short- and long-term yields would result in more than $7 billion of net interest income over the next year. Assuming three rate hikes, the bank will get a lot of that added net interest income. And who knows: If loan growth can pick up, that could boost net interest income more.\nThe outlook for investment banking and sales and trading is also likely improving for 2022. After phenomenal performances in 2020 and early 2021, many thought these lines of business, which tend to thrive during periods of volatility, might settle down -- and fixed-income, currencies, and commodities trading has slowed from record levels seen earlier this year.\nBut JPMorgan Chase analysts released a research note in October that said as inflation gets higher and bond yields creep up, that will likely create more volatility in the markets, which is when trading can pick up because there is less liquidity. With the Fed speeding up the tapering of its bond-buying program, this will also reduce the amount of liquidity in the market.\nAlso, Bank of America is coming off a strong year in investment banking with lots of mergers and acquisitions activity. In multiple quarters this year, Bank of America generated more than $2 billion in investment banking fees, which was near record levels. CEO Brian Moynihan said at a recent conference that he thinks the team can get another quarter topping $2 billion in the future.\nWith a bullish outlook in so many of Bank of America's business lines, and considering that the bank is currently buying back a lot of stock, I am optimistic that 2022 can be another strong year for earnings.\nHow to value the stock\nBanks trade relative to their earnings and also to their tangible book value (TBV), which is what a bank would be worth if it were liquidated.\n\nBAC P/E ratio data by YCharts.\nOver the past five years or so, Bank of America has traded in a range of about 7 times earnings to close to 20 times earnings. Most large banks trade in the 11-to-14 window. Its price-to-tangible book has ranged from around 100% to 200%, and 200% is certainly a strong price-to-TBV ratio in this low-rate environment.\nBut Bank of America, in my opinion, is in the strongest position it's ever been in. The bank has significantly enhanced its corporate and investment banking division, improved its deposit base, and continues to be a dominant commercial lender. Its digital capabilities are much better now as well, which will pay off as the pandemic has accelerated digital banking trends.\nBanks also solved a huge reputational issue during the pandemic that has dogged them since the Great Recession. They escaped a significant and rapid downturn with superb credit quality and were part of the solution this time around instead of the main issue behind the meltdown. Because banks looked so bad coming out of the Great Recession, I think investors have been very wary to return to them.\nFor all of these reasons, it wouldn't be unreasonable for the bank to trade at an earnings multiple in the upper echelon of its previous range. While some of the benefits of rate hikes have been priced in, I think a large-cap bank stock like Bank of America could trade at 15 times earnings, which it traded around the last time rates rose in 2017 and 2018. With EPS estimated at $3.17 in 2022, that implies a share price of $47.55, which does not imply a ton of upside from the current stock price.\nAgain, some of the benefits I've discussed from higher rates are likely priced in, but those earnings estimates from analysts for 2022 could certainly be conservative, so there could be further upside as well.\nAre there higher-growth opportunities elsewhere? Probably. But on a much longer-term basis, I have all the confidence in the world that Bank of America can keep delivering strong and consistent returns for investors.","news_type":1,"symbols_score_info":{"BAC":0.9}},"isVote":1,"tweetType":1,"viewCount":2171,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605364966,"gmtCreate":1639116337355,"gmtModify":1639116337525,"author":{"id":"3575018034770296","authorId":"3575018034770296","name":"AppleSeed","avatar":"https://static.tigerbbs.com/dd7084b7c374d1c9d55f5a6efe3e1115","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575018034770296","authorIdStr":"3575018034770296"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605364966","repostId":"1188861971","repostType":4,"isVote":1,"tweetType":1,"viewCount":1840,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}